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Introduction. For a long time there has been a progressive 
increase in the incidence of inflammatory diseases of the 
upper gastrointestinal tract (GIT). The main nosologies that 
form a prevalence of about 40% include gastritis, 
duodenitis and peptic ulcer disease. The treatment of 
gastrointestinal diseases is complicated by the resistance of 
microorganisms to most antibacterial drugs that are part of 
traditional treatment regimens prescribed to 
gastroenterological patients [1]. 
This justifies the expediency of searching for 
promising objects, in particular, among medicinal plant 
raw materials for obtaining extracts and creating drugs 
based on them, further implementation, which will expand 
the range of agents for pharmacotherapy. 
Based on previous studies, we have substantiated 
the choice of dry extract of Sanguisorba officinalis roots 
(DESOR) as the object of study and developed the 
technology of obtaining the DESOR [2, 3]. 
Screening studies were used to assess the 
pharmacological and microbiological effects of DESOR. 
Pharmacological studies performed on a model of 
subchronic erosive-hemorrhagic lesions of the gastric 
mucosa of rats caused by acetylsalicylic acid showed 
gastroprotective effect of the obtained plant object. 
Microbiological studies performed by the method of 
diffusion into agar in the modification of «wells» using test 
strains of microorganisms (S. aureus ATCC 25923, E. coli 
ATCC 25922, P. aeruginosa ATCC 27853, B. subtilis 
ATCC 6633, P. vulgaris ATCC 4636, C. albicans ATCC 
885-653) revealed sensitivity of all studied test strains to 
the object of study, in particular the greatest sensitivity to 
test strains of S. aureus and B. subtilis, as evidenced by the 
largest diameters of the zones of growth retardation of 
these microorganisms (24.17 ± 0.31 mm and 24.33 ± 0.33 
mm, respectively) [2, 4]. 
When developing new drugs, scientists pay 
special attention to the choice of dosage form, as according 
to the biopharmaceutical concept, its choice depends on the 
bioavailability of drugs. In the domestic market there are 
drugs of plant origin for use in gastroenterology in various 
dosage forms (tablets, capsules, granules, drops, liquid 
extracts, tinctures, oils, packed medicinal plant raw 
material, suppositories) [5]. 
We studied the consumer preferences for drugs 
used in diseases of the gastrointestinal tract, according to 
pharmacy experts, conducted by questionnaire. According 
to the results of processing the questionnaires, the 
commitment of consumers to herbal medicines was 
determined, and the criteria for choosing drugs implied that 
the most popular were drugs in the form of tablets. 
Thus, it is timely to create a new drug in the form 
of tablets for gastroenterology, which contains DESOR 
and has antimicrobial action. 
 
Materials and methods. Objects of the study included 
DESOR, which is a dark brown powder with a specific 
odor and bitter taste, is hygroscopic, weight loss during 
drying does not exceed 5%; excipients: fillers based on 
sugars and microcrystalline cellulose, disintegrants, 
glidants and lubricants that meet the requirements of the 
State Pharmacopoeia of Ukraine (SPU), the European 
Pharmacopoeia, regulatory and technical documentation 
and are approved for medical use. 
Determination of pharmaco-technological 
properties, namely: homogeneity of tablet weight, tablet 
abrasion, tablet resistance to crushing, tablet disintegration 
time, average tablet weight were investigated according to 
the methods given by the SPU [6]. The appearance of the 
tablets was determined visually in daylight, by observing 
them on a white background. 
Studies of the antimicrobial activity of Gastro-San 
tablets were performed at of the Biochemistry and 
Biotechnology Laboratory of the State Institution 
«Mechnikov Institute of Microbiology and Immunology of 
NAMS of Ukraine» under the direction of Candidate of 
Biological Sciences Osolodchenko T. P., by the method of 
double serial dilutions in nutrient broth. The concept study 
involved 1000 μg / ml followed by dilutions of 500; 250; 
125; 62.5; 31.25 μg / ml. The microbial load of the test 
microorganism was 5 × 105 CFU / ml. After incubation for 
48, 72 hours for Candida spp. cultures, culture tubes were 
examined in radiant light to determine the presence of 
microorganism growth. 
MIC was set at the lowest concentration of the test 
substance, which inhibited the visible growth of the 
culture. MMC was determined by dosing inoculations on a 
solid nutrient medium (Mueller-Hinton agar) of culture 
fluid from all tubes in which no growth of the 
microorganism was observed. MMC was considered to be 
the lowest concentration, which caused death of at least 
99.9% of bacteria. Additionally, the study involved control 
of culture growth in the medium without test substances in 
the solvent, control of the purity of the suspension of the 
microorganism (by seeding on non-selective media) and 
sterility of the medium. 
Statistical processing of the obtained results was 
performed using Excel software. 
 
Results and discussion. The optimal composition of the 
drug was developed under the conditional name Gastro-
San, containing DESOR at a dose of 40 mg per 1 tablet [7]. 
The choice of excipients for the development of a new drug 
in tablet form involved employment of one of the methods 
of mathematical planning of the experiment, namely hyper-
Greek-Latin square, taking into account the pharmaco-
technological parameters of both DESOR and powder 
masses with plant extract, which allowed to produce the 
drug by direct compression [7-9]. According to the results 
of the study, the following excipients were selected to be 
included in the tablets: compress sugar, prosolv 90, 
croscarmellose sodium, neuselin US 2, calcium stearate. 
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The figure shows the step-by-step technology of obtaining 
Gastro-San tablets by direct compression. 
Stage 1. Preparation of raw products and 
materials. The necessary components were weighed and 
sieved (DESOR, prosolv 90, compress sugar, 
croscarmellose sodium,  
neuselin US 2, calcium stearate). In the process of 
preparation, the availability of analytical sheets and 
permits of the quality control department, packaging 
materials, printed materials, sieve number, weight of raw 
materials were controlled. After sieving and weighing, 
containers with the prepared components were closed with 
lids, labeled and transferred to the next stages. 
Stage 2. Obtaining a mass for tableting. Weighed 
and sieved raw materials were loaded into a V-shaped 
mixer and mixed. The finished mass for tableting was 
unloaded and weighed. During mixing, the compliance 
with the formulation of the weight of the loaded 
ingredients, mixing time, quality of the intermediate 
product according to the specification and the amount of 
mass for tableting were controlled. 
Stage 3. Tableting and dedusting. The tableting 
operation was performed on a rotary tablet press. The 
following parameters of the tablet press were adjusted: 
average weight, geometric parameters; the first tablets 
obtained were checked by the rate of disintegration. In the 
process of tableting, the tablets were dedusted and 
inspected for metal inclusions. The finished tablets were 
unloaded by gravity into a container, closed with lids and 
identified by labels, weighed. In the tableting process, the 
quality control department's permission to use the tableting 
mass, geometrical parameters, basic pressure, filling depth, 
rotor speed, appearance and average weight of tablets, 
disintegration, quality of the intermediate product 
according to the specification, yield were monitored.  
Stage 4. Pre-packing of tablets. Pre-packing of 
tablets was carried out on an automatic blister packing 
machine of 10 pieces in a blister. The process parameters 
were set in accordance with the characteristics of the 
materials for the primary packing, the batch number and 
expiration date were marked. Tablets in primary packaging 
were transferred to the next stage. Availability of 
permission of the quality control department for the use of 
tablets, labeling, batch number, expiration date, 
appearance of blisters, bonding quality and yield were 
controlled. 
Stage 5. Labeling and packaging. Marking of 
packs was carried out using a marking machine, applying 
the expiration date and batch number. Labeling, batch 
number, expiration date, appearance, completeness of 
packaging and yield were controlled. 
Stage 6. Quarantine storage of finished products. 
The finished products were stored in a quarantine storage 
room, identified by the «Quarantine» label of the quality 
control department at a temperature not exceeding 250C. 
The product obtained by direct compression was 
a gray tablet with brown spots, a flat surface and a bevel. 
The pharmaco-technological properties of the obtained 
tablets were assessed, the results are presented in Table 1. 
Determination of the quality of the obtained tablets under 
the conditional name «Gastro-San» was carried out based 
on the general article of SPU «Tablets» and regulations. 
The study showed that the quality indicators of 
Gastro-San tablets met the requirements of SPU. 
The next step in the development of tablets for 
gastroenterological practice was to study their 
antimicrobial activity. Table 2 shows the results of the 
antimicrobial action of Gastro-San tablets against 
microorganisms that can cause gastrointestinal diseases. 
The study of antimicrobial activity was performed 
by the method of double serial dilutions in nutrient broth. 
According to the results of the study, the drug Gastro-San 
has a moderate antimicrobial action against reference 
strains of gram-positive, gram-negative microorganisms, 
Candida fungi and clinical isolates of microorganisms. 
Screening for gram-positive test strains of S. aureus ATCC 
25923 and S. aureus 57 showed that the inhibitory effect 
was 125 μg / ml, and ATCC 6633 - 250 μg / ml for B. 
subtilis. 
The study identified that the MIC for test strains 
of gram-negative microorganisms (P. vulgaris ATCC 
4636, E. coli ATCC 25922) was at a concentration of 250 
μg / ml. 
In relation to clinical isolates, the MIC of E. coli 
23, K. pneumonia 13, P. vulgaris 18,  
C. freundii 39, E. cloacae 54, S. enteritidis 1, S. 
typhimurium 2, S. flexneri 3 was 250 μg / ml, in relation to 
E. coli 14 (hemolytic) and P. mirabilis 33 antimicrobial 
activity was determined at the level of 500 μg / ml. The 
antifungal effect on the test strain of C. albicans ATCC 
885-653 comprised 500 μg / ml. 
The conducted microbiological study has revealed 
that the proposed drug in the form of tablets based on 
DESOR has antimicrobial action. 
 
Conclusions 
The timeliness of the development of a drug with 
antimicrobial action in the form of tablets for the treatment 
of diseases of the gastrointestinal tract has been proven. 
The technology of obtaining Gastro-San tablets by 
direct compression method is given. The study of 
pharmaco-technological indicators of the developed tablets 
with DESOR determined their compliance with the 
requirements of SPU. 
The antimicrobial action of the developed drug 
Gastro-San has been established, which opens prospects 
for its introduction into gastroenterology for the 
implementation of complex therapy of gastrointestinal 
diseases as an antimicrobial drug. 
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Table 1. Study of pharmaco-technological properties of Gastro-San tablets 
Pharmaco-technological parameters Measuring unit  
 
Research results 
Filling of a matrix Points  5 
Homogeneity of tablet weight % 1.74±0.09 
Abrasion of tablets % 0.27±0.02 
Resistance of tablets to crushing Н 152.90±1.35 
Disintegration time of tablets min 10.19±0.08 
The average weight of tablets h 0.121±0.002 
Note: n = 6, P = 95 %  
  
Table 2. Determination of antimicrobial activity of Gastro-San tablets 
Archival and clinical strains of microorganisms 
Antimicrobial action of Gastro-San, μg / ml 
MIC MMC 
S. aureus ATCC 25923 125 250 
E. coli ATCC 25922 250 500 
P. aeruginosa ATCC 27853 500 500 
B. subtilis ATCC 6633 250 250 
P. vulgaris ATCC 4636 250 500 
C. albicans ATCC 885-653 500 500 
S. aureus 57 125 250 
E. coli 23 250 500 
K. pneumonia 13 250 500 
P. vulgaris 18 250 500 
C. freundii 39 250 500 
E. cloacae 54 250 250 
E. coli 14 (hemolytic) 500 500 
S. enteritidis 1 250 500 
S. typhimurium 2 250 500 
S. flexneri 3 250 500 
P. mirabilis 33 500 500 
Development of a therapeutic agent with vegetable 
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Bezkrovna K. S., Shulga L. I., Yakuschenko V. A., 
Piminov O. F. 
Introduction. There is a progressive increase in the 
incidence of inflammatory diseases of the upper 
gastrointestinal tract. Resistance of microorganisms to 
most antibacterial drugs prescribed to gastroenterological 
patients has formed the need to search for new therapeutic 
agents, including extracts. Dry extract was obtained on 
the basis of Sanguisorba officinalis roots selected as the 
object of study. Previous biological studies have proven 
its gastroprotective and antimicrobial action, and a survey 
of pharmacy experts showed the commitment of 
consumers to drugs in tablets as the most popular dosage 
form. Therefore, the aim of the study was to develop 
drugs in the form of tablets for gastroenterology, based on 
the dry extract of Sanguisorba officinalis roots, which has 
antimicrobial action. Materials and methods. Objects of 
study involved dry extract of Sanguisorba officinalis roots 
and excipients for tableting. According to the methods of 
the State Pharmacopoeia of Ukraine, the pharmaco-
technological properties of tablets (homogeneity of mass, 
abrasion, resistance of tablets to crushing, disintegration 
time, average weight) were studied and their appearance 
was visually determined. Antimicrobial activity was 
studied of the Biochemistry and Biotechnology 
Laboratory of the State Institution «Mechnikov Institute 
of Microbiology and Immunology of NAMS of Ukraine» 
under the direction of Candidate of Biological Sciences 
Osolodchenko T. P. by the method of double serial 
dilutions in nutrient broth with statistical processing of 
data results by Excel software. The technology of 
obtaining tablets on the basis of dry extract of 
Sanguisorba officinalis roots under the conditional name 
«Gastro-San» by the method of direct compression with 
the technological scheme of their production was 
developed. The pharmaco-technological properties of 
tablets were studied and the compliance of the obtained 
indicators with the requirements of SPU was established. 
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Studies of the antimicrobial properties of Gastro-San 
tablets against reference test strains (S. aureus ATCC 
25923, E. coli ATCC 25922, B. subtilis ATCC 6633, 
P. aeruginosa ATCC 27853, P. vulgaris ATCC 4636 and 
Candida fungi) and clinical strains of microorganisms (S. 
aureus 57, E. coli 23, K. pneumonia 13, P. vulgaris 18, C. 
freundii 39, E. cloacae 54, E. coli 14 (hemolytic), S. 
enteritidis 1, S. typhimurium 2, S. flexneri 3, 
P. mirabilis 33) proved antimicrobial action of the 
developed tablets. Conclusions. The technology of 
obtaining Gastro-San tablets by direct compression has 
been developed. Assessment of pharmaco-technological 
indicators of the developed tablets was carried out and 
conformity of quality of Gastro-San tablets to 
requirements of article «Tablets» of the State 
Pharmacopoeia of Ukraine was established. The 
antimicrobial action of the drug Gastro-San has been 
established, which indicates the prospects of including the 
developed drug in the complex therapy gastrointestinal 
diseases as an antimicrobial agent.  
Key words: dry extract of Sanguisorba officinalis roots, 
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